

Amendments to the Claims:

The following Listing of the Claims replaces all prior versions and listings of the claims in this application.

Listing of the Claims:

1 (Original): A pharmaceutical composition comprising a pharmaceutically effective combination of

(i) a first compound selected from the group consisting of muscarinic receptor antagonists, 5 α -reductase inhibitors, and α -adrenergic receptor antagonists, and precursors and pharmaceutically acceptable salts thereof, and

(ii) a second compound selected from the group consisting of 5-HT_{1a} receptor agonists and antagonists, and precursors and pharmaceutically acceptable salts thereof, and optionally a pharmaceutically acceptable carrier or diluent therefor.

2 (Original): A pharmaceutical composition according to claim 1, wherein said first compound is a muscarinic receptor antagonist, or a precursor or a pharmaceutically acceptable salt thereof.

3 (Original): A composition according to claim 2, wherein said muscarinic receptor antagonist is a substituted 3,3-diphenylpropylamine.

4 (Original): A composition according to claim 3, wherein said substituted 3,3-diphenylpropylamine is selected from the group consisting of tolterodine and hydroxytolterodine.

5 (Original): A composition according to claim 4, wherein said substituted 3,3-diphenylpropylamine is tolterodine.

6 (Original): A composition according to claim 5, wherein said first compound is tolterodine L-tartrate.

7 (Original): A composition according to claim 2, wherein said muscarinic receptor antagonist is selected from oxybutynin and active derivatives thereof, such as N-desethyloxybutynin.

8 (Original): A composition according to claim 7, wherein said muscarinic receptor antagonist is oxybutynin.

9 (Original): A composition according to claim 2, wherein said muscarinic receptor antagonist is selected from darifenacin and active derivatives thereof, such as its 3'-hydroxyl metabolite.

10 (Original): A composition according to claim 9, wherein said muscarinic receptor antagonist is darifenacin.

11 (Currently Amended): A composition according to claim 1 ~~any one of claims 1-10~~, wherein said first compound is present in an amount of from about 0.1 mg to about 100 mg.

12 (Currently Amended): A composition according to claim 1 ~~any one of claims 1-11~~, wherein said second compound is a neutral 5-HT_{1a} receptor antagonist.

13 (Currently Amended): A composition according to claim 1 ~~any one of claims 1-12~~, wherein said second compound is present in an amount of from about 0.1 mg to about 1 g.

14 (Currently Amended): A composition according to claim 1 ~~any one of claims 1-13~~, wherein said first compound and said second compound are maintained in the same delivery vehicle.

15 (Currently Amended): A composition according to claim 1 ~~any one of claims 1-13~~, wherein said first compound and said second compound are maintained in different delivery vehicles.

16 (Currently Amended): A composition according to claim 1 ~~any one of claims 1-15~~, which is for treating urinary disorder in a mammal, including man.

17 (Original): A composition according to claim 16, wherein said disorder is lower urinary tract symptoms.

18 (Original): A composition according to claim 16, wherein said disorder is unstable or overactive urinary bladder.

19 (Original): A composition according to claim 16, wherein said disorder is bladder outflow obstruction.

20 (Original): A composition according to claim 16, wherein said disorder is urinary incontinence.

21 (Original): A composition according to claim 20, wherein said disorder is stress incontinence.

22 (Original): A composition according to claim 16, wherein said disorder is interstitial cystitis.

23 (Currently Amended): A composition according to claim 16 ~~any one of claims 16-22~~, which is for treating depression in said mammal, which depression is concomitant with said urinary disorder.

24-31 (Cancelled).

32 (Currently Amended): A method of therapeutical treatment of urinary disorder in a mammal, including man, comprising administering to said mammal, including man, in need of such treatment, a therapeutically effective amount of a composition according to claim 1 ~~any one of claims 1-15~~.

33 (Original): A method of therapeutical treatment according to claim 32, wherein said disorder is lower urinary tract symptoms.

34 (Original): A method of therapeutical treatment according to claim 32, wherein said disorder is unstable or overactive urinary bladder.

35 (Original): A method of therapeutical treatment according to claim 32, wherein said disorder is bladder outflow obstruction.

36 (Original): A method of therapeutical treatment according to claim 32, wherein said disorder is urinary incontinence.

37 (Original): A method of therapeutical treatment according to claim 36, wherein said disorder is stress incontinence.

38 (Original): A method of therapeutical treatment according to claim 32, wherein said disorder is interstitial cystitis.

39 (Currently Amended): A method of therapeutical treatment according to claim 32 ~~any one of claims 32-38~~, which is also for treatment of depression in said mammal, which depression is concomitant with said urinary disorder.

40 (Currently Amended): A method of therapeutical treatment according to claim 32 ~~any one of claims 32-39~~, wherein said composition is administered rectally, intravaginally, topically, orally, sublingually, intranasally, transdermally or parenterally.

41 (Currently Amended): A method of therapeutical treatment according to claim 32 ~~any one of claims 32-40~~, wherein said first compound and said second compound of said composition are simultaneously administered.

42 (Currently Amended): A method of therapeutical treatment according to claim 32 ~~any one of claims 32-40~~, wherein said first compound and said second compound of said composition are concomitantly administered.

43 (Currently Amended): A pharmaceutical kit for therapeutical treatment of urinary disorder in a mammal, including man, comprising the composition according to claim 1, wherein

- (i) a first container comprises the ~~comprising a first compound according to any one of claims 1-10~~,
- (ii) a second container comprises the ~~comprising a second compound according to claim 1 or 12~~, and optionally comprising
- (iii) instructions for use of the kit.